Jim Simons’s Immunocore IMCR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$4.94M Buy
164,000
+23,100
+16% +$747K 0.01% 1388
2025
Q4
$4.89M Sell
140,900
-1,870
-1% -$66K 0.01% 1320
2025
Q3
$5.19M Sell
142,770
-79,282
-36% -$2.69M 0.01% 1473
2025
Q2
$6.97M Buy
222,052
+131,482
+145% +$4.08M 0.01% 1311
2025
Q1
$2.69M Sell
90,570
-6,000
-6% -$180K ﹤0.01% 1809
2024
Q4
$2.85M Sell
96,570
-179,630
-65% -$5.68M ﹤0.01% 1817
2024
Q3
$8.6M Sell
276,200
-370,720
-57% -$13.5M 0.01% 1119
2024
Q2
$21.9M Buy
646,920
+82,120
+15% +$4.19M 0.04% 549
2024
Q1
$36.7M Buy
564,800
+219,700
+64% +$15.1M 0.06% 410
2023
Q4
$23.6M Sell
345,100
-111,200
-24% -$5.78M 0.04% 553
2023
Q3
$23.7M Buy
456,300
+9,000
+2% +$533K 0.04% 510
2023
Q2
$26.8M Buy
447,300
+2,700
+0.6% +$154K 0.04% 539
2023
Q1
$22M Buy
444,600
+139,500
+46% +$7.84M 0.03% 666
2022
Q4
$17.4M Buy
305,100
+210,300
+222% +$11.8M 0.02% 788
2022
Q3
$4.45M Buy
94,800
+43,900
+86% +$2.09M 0.01% 1512
2022
Q2
$1.9M Buy
50,900
+43,600
+597% +$1.42M ﹤0.01% 2223
2022
Q1
$218K Buy
+7,300
New +$184K ﹤0.01% 3610

Other funds holding IMCR

Jim Simons's IMCR Position: Q1 2026 in Review

Jim Simons increased its Immunocore (IMCR) stake by 16% in Q1 2026, buying an estimated $747K and bringing the position to 164,000 shares worth $4.94M. The position accounts for 0.01% of the portfolio, ranked #1388.

Jim Simons first reported a position in IMCR in Q1 2022 and has held it in 17 quarters since. The position peaked at $36.7M in Q1 2024. 142 funds tracked by Wall St. Rank hold IMCR as of Q1 2026.

  • Jim Simons held 164,000 shares of Immunocore worth $4.94M as of Q1 2026.
  • Jim Simons bought 23,100 Immunocore shares in Q1 2026, an estimated $747K.
  • Immunocore made up 0.01% of Jim Simons's portfolio in Q1 2026, its #1388 holding.
  • Jim Simons first reported a position in Immunocore in Q1 2022 and has held it in 17 quarters since.
  • Jim Simons's Immunocore position peaked at $36.7M in Q1 2024.
  • 142 funds tracked by Wall St. Rank held Immunocore as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.